Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2401 to 2415 of 7684 results

  1. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer ID6399

    Awaiting development [GID-TA11499] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Cabozantinib for treating advanced pancreatic or extra-pancreatic neuroendocrine tumours that have progressed after systemic treatment TSID 12078

    Awaiting development [GID-TA11613] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over TS ID 12082

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  6. Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

    Awaiting development [GID-TA11299] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]

    In development [GID-TA10904] Expected publication date: 15 January 2025

    Technology appraisal guidance
    In development

  8. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  9. Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

    In development [GID-TA11437] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Acne

    Awaiting development [GID-QS10036] Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Primary hyperparathyroidism

    Awaiting development [GID-QS10089] Expected publication date: TBC

    Quality standard
    Awaiting development

  12. School-based interventions: physical and mental health and wellbeing promotion

    In development [GID-QS10070] Expected publication date: TBC

    Quality standard
    In development

  13. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development